Our corporate headquarters are located at:
Xeris Biopharma
1375 W Fulton St.
Suite 1300
Chicago, IL 60607

Xeris Biopharma was founded in 2005.

Xeris Biopharma is incorporated in Delaware.

Xeris Biopharma commenced its initial public offering (IPO) in June 2018.

Xeris Biopharma's fiscal year ends December 31st.

Xeris Biopharma’s common stock is listed on the NASDAQ Global Select Market under the symbol “XERS”.

The transfer agent and registrar for the common stock of Xeris Biopharma is
Computershare Trust Company, N.A.
Regular Delivery:
P.O. Box 43006
Providence, RI 02940-3006

By Overnight Delivery:
150 Royal Street, Suite 101
Canton, MA 02021

For questions about your stock please contact our transfer agent, Computershare Trust Company, N.A.

Online: Computershare Investor Services, https://www-us.computershare.com/investor/Contact

Phone: (800) 736-3001 (US, Canada, Puerto Rico); (781) 575-3100 (non-US)
Email: web.queries@computershare.com

To change the address on your shareholder account, you must send both your old and new addresses to our transfer agent:

150 Royal Street, Suite 101
Canton, MA 02021

Xeris Biopharma does not have a direct stock purchase plan.

The auditor for Xeris Biopharma is KPMG LLC, located in Chicago Illinois.

Feel free to explore other parts of the site to find out more about Xeris Biopharma or contact us with inquiries.

You can view our press releases and financial reports at any time.

Xeris Biopharma's SEC Filings can be found on www.sec.gov or in the Financials section of this site.

You can learn more about the Executive Management team and Board of Directors in the Leadership section of this site.

Please feel free to contact us at your convenience.

Yes, please see form here.

Request email alerts